Martin Rogers (born 1981) is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.

Background

Rogers attended the University of New South Wales between 1999 and 2004 where he gained a double degree in chemical engineering and computer science. Between 2004 and 2007 he engaged in a number of entrepreneurial pursuits as well as worked at Macquarie Bank.[1]

Prima BioMed

Rogers was part of an investor group that effectively took control of Prima BioMed in late 2007, when he was appointed a director. At that time Prima had Phase IIa data for its CVac cancer vaccine product, but did not have the funds to progress further. Under Rogers' leadership Prima achieved four main things:

* Raised approx. A$82m in new capital. Rogers started with a 1-for-2 rights issue in October 2007 (A$2.0m)[2] and followed with Share Purchase Plans in December 2008[3] and June 2009[4] (each approx A$0.2m) and a share placement in June 2009 (A$1.5m)[5] before securing an equity funding line which allowed A$14.7m to be raised between July 2011 and March 2011. From late 2009 capital raising became easier. A third Share Purchase Plan in December 2009 raised A$13.7m[6] while a placement and associated Share Purchase Plan in June 2011 raised A$41.4m.[7] Between 2009 and 2012 the exercise of options brought in another A$8.4m (A$1.3m in 2009/10,[8] A$5.1m in 2010/11[9] and A$2.0m in 2011/12[10]).

* Experienced an increase in its share price. Prima stock re-rated 19-fold between December 2007 and April 2011, creating a company with a market value of ~A$300m.[11]

* Moved CVac into mid-stage clinical studies. The extra funding Prima was able to raise allowed CVac to be taken into Phase IIb studies from 2010 with a runway into Phase III.

* Became a Nasdaq-listed company. Prima's ADRs started trading on Nasdaq in April 2012.

Prima announced in May 2012 that Rogers would be stepping down as CEO.[12] He left Prima at the end of August 2012. By the end of tenure Prima had made it into the S&P/ASX 300.[13]

Since Prima Biomed

Since 2012 Rogers has been involved at board level in a number of ASX-listed biotech companies, including Cellmid (ASX: CDY) between September 2012[14] and June 2015;[15] Rhinomed (ASX: RNO), since September 2012;[16] OncoSil Medical (ASX: OSL) since April 2013;[17] and Actinogen (ASX: ACW), since September 2014.[18]

In 2018, Martin Rogers, of KTM Ventures, co-invested with Mike Tilley to purchase a 30% stake in cryptocurrency exchange Independent Reserve.[19][20]

References

  1. ↑ http://www.asx.com.au/asxpdf/20071016/pdf/3154n4hhtxgzr8.pdf
  2. ↑ "Company announcement - non-renounceable rights issue" (PDF). Prima BioMed. 23 October 2007. Retrieved 23 July 2015.
  3. ↑ "Company announcement - Completion of Share Purchase Plan" (PDF). Prima BioMed. 9 January 2009. Retrieved 23 July 2015.
  4. ↑ "Company announcement - Completion of Share Purchase Plan" (PDF). Prima BioMed. 29 June 2009. Retrieved 23 July 2015.
  5. ↑ "Prima BioMed - Notice of Extraordinary General Meeting" (PDF). Prima BioMed. 25 May 2009. Retrieved 23 July 2015.
  6. ↑ "Company announcement - Completion of Share Purchase Plan" (PDF). Prima BioMed. 1 December 2009. Retrieved 23 July 2015.
  7. ↑ "Company announcement - Prima BioMed raises $20 million in Share Purchase Plan" (PDF). Prima BioMed. 28 June 2011. Retrieved 23 July 2015.
  8. ↑ "Prima BioMed 2010 Annual Report" (PDF). Prima BioMed. Retrieved 23 July 2015.
  9. ↑ "Prima BioMed 2011 Annual Report" (PDF). Prima BioMed. Retrieved 23 July 2015.
  10. ↑ "Prima BioMed 2012 Annual Report" (PDF). Prima BioMed. Retrieved 23 July 2015.
  11. ↑ "Rhinomed (RNO) - Breathtaking early stage opportunity" (PDF). Rhinomed. Baillieu Holst. Retrieved 23 July 2015.
  12. ↑ http://www.asx.com.au/asxpdf/20120524/pdf/426fwpvk9p6xsb.pdf
  13. ↑ "Prima BioMed: Time to change leader". 24 May 2012.
  14. ↑ http://www.asx.com.au/asxpdf/20120919/pdf/428t55878z23cs.pdf
  15. ↑ http://www.asx.com.au/asxpdf/20150526/pdf/42ysxlscqdmj7q.pdf
  16. ↑ http://www.asx.com.au/asxpdf/20120903/pdf/428gd108fszz38.pdf
  17. ↑ http://www.asx.com.au/asxpdf/20130403/pdf/42f0v52ty3fcm2.pdf
  18. ↑ http://www.asx.com.au/asxpdf/20140827/pdf/42rs6t46n69817.pdf
  19. ↑ "Mike Tilley backs cryptocurrency exchange Independent Reserve". Australian Financial Review. 14 March 2018. Retrieved 30 October 2023.
  20. ↑ "Forget the carnage; insiders are thriving in crypto". Australian Financial Review. 23 November 2022. Retrieved 30 October 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.